Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Public Health  >  Current Article

Pharma Boom: 14 Biosimilars To Debut In The US

September 13, 2014 

The US lags behind other regulated markets, particularly the European Union, in terms of biosimilar competition. However, this is about to change soon, as there are at least 14 expensive biotech drugs that will now face generic competition from drug makers who want to sell copycat versions at a lower price.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>